Answers are grounded in this paper and cite their sources.
Real-world study shows comparable rates of non-ICANS neurologic events in multiple myeloma, suggesting a favorable treatment profile.
In this real-world study, rates of non-ICANS NEs post-cilta-cel infusion across two databases were comparable to or lower than prior trials or real-world studies, reinforcing the favorable risk-benefit profile of cilta-cel in routine practice. Graphical Abstract available for this article.
No takes yet. Share an insight, caveat, or question.
Sidana et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: